A review of the latest leadership moves in the pharma industry.
The U.S. CDC plans to drop its five-day COVID-19 isolation recommendations under new guidance planned by the agency, the Washington Post reported on Tuesday.
The European Commission on Monday approved Biogen’s Skyclarys (omaveloxolone) for the treatment of the rare genetic disorder Friedrich’s ataxia in patients aged 16 years and above.
A federal judge on Monday dismissed a lawsuit by a major pharmaceutical industry trade association challenging a new program that allows Medicare to negotiate prices with drug companies for selected costly drugs.
Gilead Sciences announced Monday it is acquiring CymaBay Therapeutics and its lead candidate seladelpar, an investigational treatment for primary biliary cholangitis, in a $4.3 billion deal.
Takeda Pharmaceutical’s therapy for an allergic inflammation of the esophagus has received approval from the U.S. FDA, the Japanese drugmaker said on Monday, capping a years-long regulatory process.
Two Florida courts last week ruled in Novo Nordisk’s favor in its legal battle against wellness clinics and compounding pharmacies for marketing counterfeit or compounded versions of its popular weight-loss drug semaglutide.
Bayer’s CEO said on Friday that the healthcare and crop chemicals group continues to firmly back its glyphosate weedkiller even after a recent courtroom loss in U.S. litigation over an alleged carcinogenic effect.
Moderna fell as much as 7% on Friday after Wall Street analysts raised concerns over faster declines in the efficacy of its experimental respiratory syncytial virus (RSV) vaccine when compared with rival shots from GSK and Pfizer.
The CEOs of Bristol Myers Squibb, Johnson & Johnson and Merck testified Thursday before the Senate health committee, defending the high U.S. prices that Americans pay for prescription drugs compared to other countries based on patient value and the need to fund innovation and R&D costs.
